

RISPOVAL 3 BRSV PI3 BVD LYOPHILISATE AND SUSPENSION FOR SUSPENSION FOR INJECTION FOR CATTLE

Authorised

- Bovine parainfluenza virus 3, strain RLB103, Live
- Bovine viral diarrhoea virus 1, strain 5960, Inactivated
- Bovine viral diarrhoea virus 1, strain 6309, Inactivated
- Bovine respiratory syncytial virus, strain 375, Live

Product identification

Medicine name:

RISPOVAL 3 BRSV PI3 BVD LYOPHILISATE AND SUSPENSION FOR SUSPENSION FOR INJECTION FOR CATTLE

Rispoval 3 BRSV Pi3 BVD, süstesuspensiooni lüofilisaat ja suspensioon veistele

Active substance:

Bovine parainfluenza virus 3, strain RLB103, Live

Bovine viral diarrhoea virus 1, strain 5960, Inactivated

Bovine viral diarrhoea virus 1, strain 6309, Inactivated

Bovine respiratory syncytial virus, strain 375, Live

Target species:

Cattle

Route of administration:

Intramuscular use

Product details

Active substance and strength:

Bovine parainfluenza virus 3, strain RLB103, Live
100000.00 50% cell culture infectious dose / 1.00 Dose

Bovine viral diarrhoea virus 1, strain 5960, Inactivated
3.00 log2 serum neutralising unit(s) / 1.00 Dose

Bovine viral diarrhoea virus 1, strain 6309, Inactivated
3.00 log2 serum neutralising unit(s) / 1.00 Dose

Bovine respiratory syncytial virus, strain 375, Live
100000.00 50% cell culture infectious dose / 1.00 Dose

Pharmaceutical form:

Lyophilisate and suspension for suspension for injection

Withdrawal period by route of administration:

Intramuscular use:

-

Cattle

- All relevant tissues. 0 day

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI02AH

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Estonia

Package description:

Available only in French

Available only in [French](#)

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Zoetis Belgium

Marketing authorisation date:

22/05/2005

Manufacturing sites for batch release:

Zoetis Belgium

Responsible authority:

State Agency Of Medicines

Authorisation number:

1306

Date of authorisation status change:

22/05/2005

Reference member state:

France

Procedure number:

FR/V/0146/001

Concerned member states:

Belgium Bulgaria Czechia Estonia Germany Hungary Ireland Latvia
Lithuania Luxembourg Netherlands Poland Portugal Romania Slovakia
Slovenia Spain United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.